<DOC>
	<DOCNO>NCT03078582</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy RA101495 patient Paroxysmal Nocturnal Hemoglobinuria ( PNH ) . There two group patient study : first group include patient never receive eculizumab treatment PNH . The second group include patient receive treatment eculizumab least 6 month prior study . Patients treat RA101495 12 week .</brief_summary>
	<brief_title>Phase 2 Safety Efficacy Study RA101495 Treat PNH Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Diagnosis PNH flow cytometry For treatment naive patient : subject must receive treatment eculizumab prior Screening Period must lactate dehydrogenase ( LDH ) level â‰¥2 time upper limit normal ( xULN ) Screening For patient previously receive eculizumab : subject must receive treatment eculizumab least 6 month prior Screening History meningococcal disease Current systemic infection suspicion active bacterial infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PNH</keyword>
</DOC>